

## Supplementary materials:

### Statistical methods supplement

**eTable 1:** Comparison of seroreactivity in specimens from Lab A v. Lab B from Washington state and the New York City metro region.

**eTable 2. Estimated number of infections based on seroprevalence estimates and comparison with the number of reported cases as of the the date seven days prior to the start of specimen collection for six sites.**

**efigure 1 a-f. Geographic distribution of serology specimens by zip code for A) Washington State for the subset of samples for which more specific geographic information was available (Lab A specimens); B) New York City Metro Region for the subset of samples for which more specific geographic information was available (Lab A specimens); C) South Florida; D) Missouri; E) Utah; and F) Connecticut.**

**eFigure 2 a-f. Timelines indicating dates of sample collection (blue), the time period when infections resulting in reactive antibody tests most likely occurred (pink), and the cumulative number of cases reported by day<sup>10</sup> for: A) the Puget Sound region of Washington state; B) the New York City metro region. C) South Florida; D) Missouri; E) Utah; and F) Connecticut.**

### Supplement: Statistical Methods

To create point estimates of prevalence, we expressed the rates ( $R_{obs}$ ) calculated from our observed sample as a function of the true population prevalence  $P$ , lab assay sensitivity (Sens), and specificity (Spec) (Equation 1); applied our point estimates of our laboratory assay sensitivity and specificity (Equation 2); and solved for population prevalence (Equation 3).

$$R_{obs} = P * Sens + (1-P) * (1-Spec) \quad [1]$$

$$R_{obs} = P * (0.96) + (1-P) * (0.007) \quad [2]$$

$$P = (R_{obs} - 0.007) / 0.953 \quad [3]$$

To create confidence intervals around our estimates, we used a two-stage non-parametric bootstrap with 10,000 draws. In the first stage, we account for variability in the sensitivity and specificity of the laboratory assay, which were 96.0% sensitive (confidence interval 89.98 – 98.89%), and 99.3% specific (confidence interval 85.38 – 98.9%), by drawing at random from a binomial distribution of the assay validation dataset.<sup>10</sup>

In the second stage, we drew a bootstrap sample of specimens, then used the sensitivity and specificity drawn in the first stage to estimate probability of false negative and false positive results, based on sample prevalence in each age group, and applied that probability to our bootstrap sample, resulting in a bootstrap sample that is corrected for assay accuracy.

We then used the distribution of all corrected bootstrap sample to calculate confidence intervals at the 2.5<sup>th</sup> and 97.5<sup>th</sup> percentile of the bootstrap distributions of the three statistics: Age-specific, sex-specific, and age-sex-standardized COVID-19 attack rates.

**Age-specific and sex-specific rates.** Rates for individual strata are the number of reactive results divided by total tested for specimens within that stratum.

**Age and sex standardization.** To create age-sex standardization weights, we obtained denominator data from U.S. census population projections by age and sex. One subset of specimens were not associated to specific zip codes. Per the commercial source of the specimens, the majority of specimens from NY and WA were from the NYC metro region and the Puget Sound region, respectively. They were standardized to the populations of the New York New Jersey Pennsylvania Metropolitan statistical site<sup>1</sup>, or from the Washington State population,<sup>2</sup> respectively. The second subset of specimens were associated with zip codes, so we used county-level census estimates by sex and five-year

age band<sup>3</sup> and created standard populations from the aggregate of the five counties in each state representing the most specimens. Census population estimates were assigned to our study age groups and then aggregated. Estimates that did not exactly correspond to the study age groups were apportioned assuming equal numbers of each age per age group. For example, we apportioned 20% of the 15-19 census age group population into our 19-49 age group.

Then standard rates were calculated for the  $i$ th age-sex stratum  $\{i=1\dots k\}$  with  $p$  reactive results of  $n$  total tests and  $N$  estimated census population.

$$\sum_{i=1}^k \frac{r_i N_i}{N}, r_i = \frac{\sum_{j=1}^n p_j}{n_i}$$

References:

- 1) U.S. Census Bureau (2018) via Census Reporter. New York New Jersey Pennsylvania Metropolitan Site - data source overview:  
[https://censusreporter.org/data/table/?table=B01001&primary\\_geo\\_id=31000US35620&geo\\_ids=31000US35620,04000US36,33000US408,01000US#](https://censusreporter.org/data/table/?table=B01001&primary_geo_id=31000US35620&geo_ids=31000US35620,04000US36,33000US408,01000US#)  
Raw dataset:  
[https://api.censusreporter.org/1.0/data/download/latest?table\\_ids=B01001&geo\\_ids=31000US35620,04000US36,33000US408,01000US&format=xlsx](https://api.censusreporter.org/1.0/data/download/latest?table_ids=B01001&geo_ids=31000US35620,04000US36,33000US408,01000US&format=xlsx)
- 2) U.S. Census bureau (2018). Data source overview: <https://www.census.gov/data/tables/time-series/demo/pepsect/2010s-state-detail.html>  
Raw dataset: <https://www2.census.gov/programs-surveys/pepsect/tables/2010-2018/state/asrh/sc-est2018-agesex-civ.csv>
- 3) U.S. Census Bureau (2019). County-level population estimates by age and sex, file raw dataset: <https://www2.census.gov/programs-surveys/pepsect/datasets/2010-2018/counties/asrh/cc-est2018-alldata.csv>
- 4) Confidence intervals for an age-adjusted rate:  
[https://www.health.pa.gov/topics/HealthStatistics/Statistical-Resources/UnderstandingHealthStats/Documents/Confidence\\_Intervals\\_for\\_an\\_Age\\_Adjusted\\_Rate.pdf](https://www.health.pa.gov/topics/HealthStatistics/Statistical-Resources/UnderstandingHealthStats/Documents/Confidence_Intervals_for_an_Age_Adjusted_Rate.pdf)
- 5) Stats with R: comparing means: z and t tests: [https://mgimond.github.io/Stats-in-R/z\\_t\\_tests.html](https://mgimond.github.io/Stats-in-R/z_t_tests.html)
- 6) Indiana Cancer Mortality Report: State and County Data 1992 – 1996 Statistical appendix A.  
[https://www.in.gov/isdh/reports/cancermort/1992-96/app\\_a.h](https://www.in.gov/isdh/reports/cancermort/1992-96/app_a.h)

**eTable 1:** Comparison of seroreactivity in specimens from Lab A v. Lab B from Washington state and the New York City metro region.

## New York City metro region

	Lab A	Lab B
N Specimens tested with result & demographics	682	1800
N Reactive <sup>a</sup> (%)	64 (9.38%)	89 (4.94%)
Age-sex-adjusted rate full sample	11.51%	5.70%
Standard error (SE) of age-sex-adjusted rate (rate / $\sqrt{pos}$ )	1.44%	0.6%
SE of the difference in rates (pooled SE)	1.56%	
z-score for the difference (difference / pooled SE)	3.72	
P value (probability of differing this much by chance)	<0.01	
Age-sex-adjusted rate, bootstrap	9.07%	5.44%
Bootstrap of the z-score of the difference	2.69	
P value for z-score in the bootstrap	<0.01	

## Washington State

	Lab A	Lab B
N Specimens tested with result & demographics	1488	1777
N Reactive <sup>a</sup> (%)	26	33
Age-sex-adjusted rate full sample	1.86	1.53
SE of age-sex-adjusted rate (rate / $\sqrt{pos}$ )	0.36%	0.27%
SE of the difference in rates (pooled SE)	0.45%	
z-score for the difference (difference / pooled SE)	0.72	
P value (probability of differing this much by chance)	0.47	
Age-sex-adjusted rate, bootstrap	1.55%	1.16%
Bootstrap of the z-score of the difference	0.96	
P value for z-score in the bootstrap	0.034	

<sup>a</sup> A specimen was considered reactive if, on confirmatory testing with the assay described in Freeman, et al.<sup>9</sup>, at a background corrected OD of 0.4, at a serum dilution of 1:100, it had a signal to threshold ratio of >1. (References: Statistical supplement references 4-6.)


**eTable 2. Estimated number of infections based on seroprevalence estimates and comparison with the number of reported cases as of the the date seven days prior to the start of specimen collection for six sites.**

	WA	NY	FL	MO	UT	CT
Date 7 days prior to start of specimen collection	3/16/20	3/16/20	3/29/20	4/13/20	4/13/20	4/19/20
Catchment description	King, Snohomish, Pierce, Kitsap and Grays Harbor	Manhattan, Bronx, Queens, Kings, Nassau	Miami-Dade, Broward, Palm Beach, Martin	State-wide	Adults 19+ (State-wide)	State-wide
Catchment population	4,273,548	9,260,870	6,345,345	6,110,800	2,173,082	3,562,989
Cumulative prevalence <sup>a</sup>	1.13% (0.70 – 1.94)	6.93% (5.02 – 8.92)	1.85% (1.00-3.23)	2.65% (1.65-3.86)	2.18% (1.21-3.43)	4.94% (3.61 – 6.52)
Cases reported by date seven days prior to beginning of specimen collection	734	545	3,328	4,385	2,050 <sup>b</sup>	19,815
Estimated cumulative infections	48,291 (29,915 – 82,907)	641,778 (464,896 – 826,070)	117,389 (63,453 – 204,955)	161,936 (100,828 – 235,877)	47,373 (26,294 – 74,537)	176,012 (128,624 – 232,307)
Estimated infections/reported cases (range) <sup>c</sup>	65.8 (40.8 - 113.0)	1,177.6 (853.0 - 1,515.7)	35.3 (19.1 - 61.6)	36.9 (23.0 - 53.8)	23.1 (12.8 - 36.4)	8.9 (6.5 - 11.7)


<sup>a</sup> Standardized to the age and sex distribution of the counties in each region from which most specimens originated. All estimates are adjusted for test performance characteristics (specificity 99.3% (confidence interval [CI] 98.32 – 99.88%); sensitivity 96.0% (CI 89.98 – 98.89%). <sup>b</sup> The number of specimens for persons aged 0-18 years was inadequate, and those <18 years were excluded from the analysis. Estimates are for adults ≥19 year. Case report data was not available by age in all cases and was estimated by publicly reported age grouping. <sup>c</sup> Estimated number of times greater for infections suggested by seroprevalence estimates compared with reported cases.

efigure 1 a-f. Geographic distribution of serology specimens by zip code for A) Washington State for the subset of samples for which more specific geographic information was available (Lab A specimens); B) New York City Metro Region for the subset of samples for which more specific geographic information was available (Lab A specimens); C) South Florida; D) Missouri; E) Utah; and F) Connecticut.


**A) Washington State (Puget Sound Region)**




**B) New York City Metro Region**




C) South Florida




D) Missouri



### E) Utah




### F) Connecticut




eFigure 2 a-f. Timelines indicating dates of sample collection (blue), the time period when infections resulting in reactive antibody tests most likely occurred (pink), and the cumulative number of cases reported by day<sup>10</sup> for: A) the Puget Sound region of Washington state; B) the New York City metro region. C) South Florida; D) Missouri; E) Utah; and F) Connecticut.

The striped site indicates dates during which infection may have occurred, but antibodies may not yet be detectable. Note that January 20, 2020 was the date of the first reported case in the United States.


A) Washington




B) New York City Metro Region




C) South Florida



D) Missouri



E) Utah



### F) Connecticut

